Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H1 2015

Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H1 2015', provides an overview of the Keratoconjunctivitis sicca (Dry Eye)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Keratoconjunctivitis sicca (Dry Eye) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Keratoconjunctivitis sicca (Dry Eye) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Keratoconjunctivitis sicca (Dry Eye) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Keratoconjunctivitis sicca (Dry Eye) Overview 8

Therapeutics Development 9

Pipeline Products for Keratoconjunctivitis sicca (Dry Eye)-Overview 9

Pipeline Products for Keratoconjunctivitis sicca (Dry Eye)-Comparative Analysis 10

Keratoconjunctivitis sicca (Dry Eye)-Therapeutics under Development by Companies 11

Keratoconjunctivitis sicca (Dry Eye)-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Keratoconjunctivitis sicca (Dry Eye)-Products under Development by Companies 19

Keratoconjunctivitis sicca (Dry Eye)-Companies Involved in Therapeutics Development 22

Allergan, Inc. 22

Celsus Therapeutics Plc 23

Circadian Technologies Limited 24

Digna Biotech, S.L. 25

Dompe Farmaceutici S.p.A. 26

Dong-A Socio Group 27

Eleven Biotherapeutics Inc. 28

EyeGate Pharmaceuticals, Inc. 29

HanAll Biopharma Co., Ltd. 30

Herantis Pharma plc. 31

Huons Co., Ltd. 32

InSite Vision Incorporated 33

Kainos Medicine, Inc. 34

Kala Pharmaceuticals, Inc. 35

Kissei Pharmaceutical Co., Ltd. 36

Laboratorios Sophia S.A. de C.V. 37

Lipicard Technologies Limited 38

LTT Bio-Pharma Co., Ltd. 39

Merck & Co., Inc. 40

Mimetogen Pharmaceuticals Inc. 41

Neuroptis Biotech 42

NovaBay Pharmaceuticals, Inc. 43

Novaliq GmbH 44

Ocular Therapeutix, Inc. 45

OncoNOx ApS 46

Otsuka Holdings Co., Ltd. 47

Parion Sciences, Inc. 48

R-Tech Ueno, Ltd. 49

RegeneRx Biopharmaceuticals, Inc. 50

Resolvyx Pharmaceuticals, Inc 51

Santen Pharmaceutical Co., Ltd. 52

Scynexis, Inc. 53

Seikagaku Corporation 54

Shire Plc 55

SIFI S.p.A 56

Winston Pharmaceuticals, Inc. 57

Xigen SA 58

Keratoconjunctivitis sicca (Dry Eye)-Therapeutics Assessment 59

Assessment by Monotherapy Products 59

Assessment by Target 60

Assessment by Mechanism of Action 63

Assessment by Route of Administration 65

Assessment by Molecule Type 67

Drug Profiles 69

cyclosporine-Drug Profile 69

cyclosporine-Drug Profile 70

cyclosporine-Drug Profile 73

cyclosporine-Drug Profile 74

cyclosporine Nanoemulsion-Drug Profile 75

dexamethasone acetate-Drug Profile 76

dexamethasone acetate SR-Drug Profile 78

diclofenac sodium-Drug Profile 79

diquafosol tetrasodium-Drug Profile 80

disitertide-Drug Profile 82

EBI-005-Drug Profile 85

HL-036-Drug Profile 87

ISV-101-Drug Profile 88

KBP-7306-Drug Profile 89

KeraKlear-Drug Profile 90

KL-7016-Drug Profile 91

KM-401-Drug Profile 92

Lacripep-Drug Profile 93

lifitegrast-Drug Profile 94

loteprednol etabonate-Drug Profile 97

MIMD-3-Drug Profile 99

NOP-3-Drug Profile 100

NOP-5-Drug Profile 101

NVC-638-Drug Profile 102

NVC-704-Drug Profile 103

NVC-727-Drug Profile 104

OPX-1-Drug Profile 105

OTX-101-Drug Profile 106

OX-1001-Drug Profile 107

ozagrel-Drug Profile 108

P-1037-Drug Profile 109

P-17-Drug Profile 110

P-321-Drug Profile 112

plastoquinone decyl triphenylphosphonium bromide-Drug Profile 113

PRO-148-Drug Profile 115

rebamipide-Drug Profile 117

recoflavone-Drug Profile 119

Recombinant Human Nerve Growth Factor-Drug Profile 121

RGN-259-Drug Profile 122

RU-101-Drug Profile 124

ruclosporin-Drug Profile 125

RX-10005-Drug Profile 126

RX-20001-Drug Profile 127

SF-104-Drug Profile 128

SI-614-Drug Profile 129

Urocanic Acid-Drug Profile 130

VGX-100-Drug Profile 132

XG-104-Drug Profile 134

zucapsaicin-Drug Profile 135

Keratoconjunctivitis sicca (Dry Eye)-Recent Pipeline Updates 137

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects 159

Keratoconjunctivitis sicca (Dry Eye)-Discontinued Products 163

Keratoconjunctivitis sicca (Dry Eye)-Product Development Milestones 164

Featured News & Press Releases 164

Appendix 171

Methodology 171

Coverage 171

Secondary Research 171

Primary Research 171

Expert Panel Validation 171

Contact Us 171

Disclaimer 172

List of Tables

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2015 13

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye)-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 16

Number of Products under Development by Companies, H1 2015 (Contd..1) 17

Number of Products under Development by Companies, H1 2015 (Contd..2) 18

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Development, H1 2015 21

Comparative Analysis by Unknown Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Allergan, Inc., H1 2015 26

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Celsus Therapeutics Plc, H1 2015 27

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Circadian Technologies Limited, H1 2015 28

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Digna Biotech, S.L., H1 2015 29

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Dompe Farmaceutici S.p.A., H1 2015 30

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Dong-A Socio Group, H1 2015 31

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Eleven Biotherapeutics Inc., H1 2015 32

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by EyeGate Pharmaceuticals, Inc., H1 2015 33

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 34

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Herantis Pharma plc., H1 2015 35

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Huons Co., Ltd., H1 2015 36

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by InSite Vision Incorporated, H1 2015 37

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Kainos Medicine, Inc., H1 2015 38

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Kala Pharmaceuticals, Inc., H1 2015 39

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 40

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Laboratorios Sophia S.A. de C.V., H1 2015 41

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Lipicard Technologies Limited, H1 2015 42

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 43

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Merck & Co., Inc., H1 2015 44

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Mimetogen Pharmaceuticals Inc., H1 2015 45

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Neuroptis Biotech, H1 2015 46

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015 47

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Novaliq GmbH, H1 2015 48

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Ocular Therapeutix, Inc., H1 2015 49

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by OncoNOx ApS, H1 2015 50

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 51

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Parion Sciences, Inc., H1 2015 52

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by R-Tech Ueno, Ltd., H1 2015 53

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015 54

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Resolvyx Pharmaceuticals, Inc, H1 2015 55

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 56

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Scynexis, Inc., H1 2015 57

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Seikagaku Corporation, H1 2015 58

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Shire Plc, H1 2015 59

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by SIFI S.p.A, H1 2015 60

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Winston Pharmaceuticals, Inc., H1 2015 61

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Xigen SA, H1 2015 62

Assessment by Monotherapy Products, H1 2015 63

Number of Products by Stage and Target, H1 2015 65

Number of Products by Stage and Mechanism of Action, H1 2015 68

Number of Products by Stage and Route of Administration, H1 2015 70

Number of Products by Stage and Molecule Type, H1 2015 72

Keratoconjunctivitis sicca (Dry Eye) Therapeutics-Recent Pipeline Updates, H1 2015 141

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects, H1 2015 163

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects (Contd..1), H1 2015 164

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects (Contd..2), H1 2015 165

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects (Contd..3), H1 2015 166

Keratoconjunctivitis sicca (Dry Eye)-Discontinued Products, H1 2015 167

List of Figures

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2015 13

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye)-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 15

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Products, H1 2015 21

Assessment by Monotherapy Products, H1 2015 63

Number of Products by Top 10 Targets, H1 2015 64

Number of Products by Stage and Top 10 Targets, H1 2015 64

Number of Products by Top 10 Mechanism of Actions, H1 2015 67

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 67

Number of Products by Top 10 Routes of Administration, H1 2015 69

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 69

Number of Products by Top 10 Molecule Types, H1 2015 71

Number of Products by Stage and Top 10 Molecule Types, H1 2015 71

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Allergan, Inc.

Celsus Therapeutics Plc

Circadian Technologies Limited

Digna Biotech, S.L.

Dompe Farmaceutici S.p.A.

Dong-A Socio Group

Eleven Biotherapeutics Inc.

EyeGate Pharmaceuticals, Inc.

HanAll Biopharma Co., Ltd.

Herantis Pharma plc.

Huons Co., Ltd.

InSite Vision Incorporated

Kainos Medicine, Inc.

Kala Pharmaceuticals, Inc.

Kissei Pharmaceutical Co., Ltd.

Laboratorios Sophia S.A. de C.V.

Lipicard Technologies Limited

LTT Bio-Pharma Co., Ltd.

Merck & Co., Inc.

Mimetogen Pharmaceuticals Inc.

Neuroptis Biotech

NovaBay Pharmaceuticals, Inc.

Novaliq GmbH

Ocular Therapeutix, Inc.

OncoNOx ApS

Otsuka Holdings Co., Ltd.

Parion Sciences, Inc.

R-Tech Ueno, Ltd.

RegeneRx Biopharmaceuticals, Inc.

Resolvyx Pharmaceuticals, Inc

Santen Pharmaceutical Co., Ltd.

Scynexis, Inc.

Seikagaku Corporation

Shire Plc

SIFI S.p.A

Winston Pharmaceuticals, Inc.

Xigen SA

Keratoconjunctivitis sicca (Dry Eye) Therapeutic Products under Development, Key Players in Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Keratoconjunctivitis sicca (Dry Eye) Pipeline Overview, Keratoconjunctivitis sicca (Dry Eye) Pipeline, Keratoconjunctivitis sicca (Dry Eye) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com